Literature DB >> 26045294

BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.

Judith M Boer1, João R M Marchante1, William E Evans2, Martin A Horstmann3, Gabriele Escherich3, Rob Pieters4, Monique L Den Boer5.   

Abstract

Entities:  

Keywords:  BCR-ABL1-like ALL; CRLF2; IKZF1; JAK2; dic(9;20); iAMP21; kinase; prognosis; translocation

Mesh：

Substances：

Year:  2015        PMID： 26045294      PMCID： PMC4800707          DOI： 10.3324/haematol.2015.124941

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Authors:  Brent W Weston; Melissa A Hayden; Kathryn G Roberts; Susan Bowyer; Johann Hsu; George Fedoriw; Kathleen W Rao; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

2.  Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Authors:  Etienne Lengline; Kheïra Beldjord; Hervé Dombret; Jean Soulier; Nicolas Boissel; Emmanuelle Clappier
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 3.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

5.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

6.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.

Authors:  Mignon L Loh; Jinghui Zhang; Richard C Harvey; Kathryn Roberts; Debbie Payne-Turner; Huining Kang; Gang Wu; Xiang Chen; Jared Becksfort; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Brent Wood; Michael J Borowitz; Meenakshi Devidas; Daniela S Gerhard; Paul Bowman; Eric Larsen; Naomi Winick; Elizabeth Raetz; Malcolm Smith; James R Downing; Cheryl L Willman; Charles G Mullighan; Stephen P Hunger
Journal:  Blood       Date:  2012-12-04       Impact factor: 22.113

7.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors:  Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

8.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Authors:  M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

10.  Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

Authors:  Arian van der Veer; Esmé Waanders; Rob Pieters; Marieke E Willemse; Simon V Van Reijmersdal; Lisa J Russell; Christine J Harrison; William E Evans; Vincent H J van der Velden; Peter M Hoogerbrugge; Frank Van Leeuwen; Gabriele Escherich; Martin A Horstmann; Leila Mohammadi Khankahdani; Dimitris Rizopoulos; Hester A De Groot-Kruseman; Edwin Sonneveld; Roland P Kuiper; Monique L Den Boer
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113
View more
  29 in total

1.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

2.  Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

Authors:  Valérie de Haas; Nofisat Ismaila; Anjali Advani; Daniel A Arber; Raetasha S Dabney; Dipti Patel-Donelly; Elizabeth Kitlas; Rob Pieters; Ching-Hon Pui; Kendra Sweet; Ling Zhang
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

Review 3.  Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.

Authors:  Ching-Hon Pui; Kathryn G Roberts; Jun J Yang; Charles G Mullighan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08

4.  High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Authors:  Susan L Heatley; Teresa Sadras; Chung H Kok; Eva Nievergall; Kelly Quek; Phuong Dang; Barbara McClure; Nicola Venn; Sarah Moore; Jeffrey Suttle; Tamara Law; Anthea Ng; Walter Muskovic; Murray D Norris; Tamas Revesz; Michael Osborn; Andrew S Moore; Ram Suppiah; Chris Fraser; Frank Alvaro; Timothy P Hughes; Charles G Mullighan; Glenn M Marshall; Luciano Dalla Pozza; David T Yeung; Rosemary Sutton; Deborah L White
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 5.  Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Sarah K Tasian
Journal:  Blood Adv       Date:  2020-01-14

Review 6.  Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.

Authors:  Tobias Herold; Nicola Gökbuget
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

7.  Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Authors:  Sabina Chiaretti; Monica Messina; Sara Grammatico; Alfonso Piciocchi; Anna L Fedullo; Filomena Di Giacomo; Nadia Peragine; Valentina Gianfelici; Alessia Lauretti; Rohan Bareja; Maria P Martelli; Marco Vignetti; Valerio Apicella; Antonella Vitale; Loretta S Li; Cyril Salek; Olivier Elemento; Giorgio Inghirami; David M Weinstock; Anna Guarini; Robin Foà
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 8.  Novel Therapies in Acute Lymphoblastic Leukemia.

Authors:  Kathleen W Phelan; Anjali S Advani
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

9.  Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Authors:  Tobias Herold; Stephanie Schneider; Klaus H Metzeler; Martin Neumann; Luise Hartmann; Kathryn G Roberts; Nikola P Konstandin; Philipp A Greif; Kathrin Bräundl; Bianka Ksienzyk; Natalia Huk; Irene Schneider; Evelyn Zellmeier; Vindi Jurinovic; Ulrich Mansmann; Wolfgang Hiddemann; Charles G Mullighan; Stefan K Bohlander; Karsten Spiekermann; Dieter Hoelzer; Monika Brüggemann; Claudia D Baldus; Martin Dreyling; Nicola Gökbuget
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

Review 10.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.

Authors:  Anthony V Moorman
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.